stockrow
Friday 6 November 2026
Export CING’s income statement to Excel — free account
Cingulate Inc.
CING Healthcare Biotechnology
- EPS
- +58.7%
- Free cash flow
- −24.3%
Quarter to June 2026, against a year earlier
4.26
0.02
+0.47%
Follow CING
Alert me
Target Price Range
Analyst price targets
Free accountTen years at a glance
| Ten-year view | Analyst estimates Powerpack | |||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Group | Line | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM Jun ’26 | Trend | 10 yrs | 2026e | 2027e | 2028e | Next 3/yr |
| Income, $m | ||||||||||||||||||
| Income, $m | Revenue | — | — | — | — | — | — | — | — | — | — | — | — | 22 | 22 | 33 | +21.7% | |
| Gross margin, % | — | — | — | 0.00 | 0.00 | 0.00 | 0.00 | — | — | — | 0.00 | 0.0 pt | ||||||
| EBT | — | — | — | (12) | (7) | (21) | (18) | (24) | (17) | (22) | (29) | +11.7% | ||||||
| EBT margin, % | — | — | — | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.0 pt | ||||||
| Net income | — | 0 | — | (12) | (7) | (21) | (18) | (24) | (17) | (22) | (29) | n/m | ||||||
| Per share, $ | ||||||||||||||||||
| Per share, $ | Revenue | — | — | — | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | n/m | |||||
| Earnings | — | — | — | (10.93) | (12.70) | (669.87) | (374.55) | (312.12) | (10.86) | (4.44) | (3.68) | (13.9%) | ||||||
| Cash flow | — | — | — | (8.34) | (12.04) | (337.63) | (316.39) | (200.46) | (12.10) | (3.41) | (1.57) | (13.8%) | ||||||
| Capex | — | — | — | 0.00 | (0.71) | (26.37) | (3.06) | (2.99) | (0.14) | (0.03) | (0.02) | n/m | ||||||
| Free cash flow | — | — | — | (8.34) | (12.76) | (364.00) | (319.45) | (203.45) | (12.24) | (3.44) | (1.59) | (13.7%) | ||||||
| Book value | — | — | — | 0.58 | 2.29 | 674.55 | 77.33 | (91.59) | 4.89 | 0.50 | 1.78 | (2.6%) | ||||||
| Shares, m | — | — | — | 1 | 1 | 0 | 0 | 0 | 2 | 5 | 8 | +29.8% | ||||||
| Valuation, × | ||||||||||||||||||
| Valuation, × | P/E | — | — | — | — | — | — | — | — | — | — | 0 | — | |||||
| P/S | — | — | — | — | — | — | — | — | — | — | 0 | — | ||||||
| P/B | — | — | — | — | — | — | — | — | — | — | 0 | — | ||||||
| EV/Sales | — | — | — | — | — | — | — | — | — | — | 0 | — | ||||||
| EV/FCF | — | — | — | — | — | — | — | — | — | — | 0 | — | ||||||
| Cash, $m | ||||||||||||||||||
| Cash, $m | Operating cash flow | — | — | — | (9) | (7) | (10) | (16) | (15) | (18) | (17) | (21) | +11.9% | |||||
| Capex | — | — | — | (1) | 0 | (1) | 0 | 0 | 0 | 0 | 0 | (26.4%) | ||||||
| Free cash flow | — | — | — | (9) | (7) | (11) | (16) | (15) | (19) | (17) | (21) | +12.0% | ||||||
| Balance, $m | ||||||||||||||||||
| Balance, $m | Working capital | — | — | — | (2) | (2) | 18 | 1 | (10) | 8 | 2 | 22 | n/m | |||||
| Net debt | — | — | — | 2 | (1) | (16) | (5) | 0 | (10) | (10) | (28) | n/m | ||||||
| Shareholders’ equity | — | — | — | 1 | 1 | 21 | 4 | (7) | 7 | 3 | 23 | +26.4% | ||||||
| Returns, % | ||||||||||||||||||
| Returns, % | ROA | — | — | — | (437.29) | (129.80) | (144.45) | (103.09) | (315.98) | (180.43) | (149.98) | (123.76) | +287.3 pt | |||||
| ROIC | — | — | — | 0.00 | (3,023.99) | (294.59) | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.0 pt | ||||||
| ROE | — | — | — | (1,210.11) | (752.88) | (187.12) | (142.98) | 1,575.62 | (5,650.78) | (450.60) | (198.74) | +759.5 pt | ||||||
| People | ||||||||||||||||||
| People | Employees | — | — | — | — | 13 | 16 | 15 | 13 | 13 | 14 | — | +1.5% | |||||
| Revenue/emp, $m | — | — | — | — | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | — | n/m | ||||||
Negative figures in brackets.
estimates
Fundamentals updated 26 Oct 2026
Cingulate Inc. vs peers in Biotechnology (Q) = latest quarter vs a year earlier
| Company | Market cap | P/E | Fwd P/E | Revenue growth (Q) | EPS growth (Q) | FCF growth (Q) | Gross margin (Q) | EBIT margin (Q) | Compare |
|---|---|---|---|---|---|---|---|---|---|
| CSBR Champions Oncology, Inc. | $66.3M | — (loss-making) | — (loss-making) | +8.84% (above 0%: growing) | n/m | −198.74% (below 0%: shrinking) | 50.54% | (2.69%) | Compare |
| CNXU Conexeu Sciences Inc. | $65.4M | — (loss-making) | — | — | n/m | −1,084.33% (below 0%: shrinking) | — | 0.00% | Compare |
| CING Cingulate Inc. | $61.7M | — (loss-making) | — | — | n/m | −24.28% (below 0%: shrinking) | 0.00% | 0.00% | |
| FBIO Fortress Biotech, Inc. | $61.4M | 0.6× | 0.8× | +14.04% (above 0%: growing) | n/m | −115.37% (below 0%: shrinking) | 67.18% | (53.46%) | Compare |
| TENX Tenax Therapeutics, Inc. | $61.0M | — (loss-making) | — | −77.98% (below 0%: shrinking) | n/m | −125.93% (below 0%: shrinking) | 0.00% | 0.00% | Compare |
| CGTX Cognition Therapeutics, Inc. | $60.4M | — (loss-making) | — | — | n/m | +45.35% (above 0%: growing) | 0.00% | 0.00% | Compare |
| CRDF Cardiff Oncology, Inc. | $58.8M | — (loss-making) | — (loss-making) | −14.05% (below 0%: shrinking) | n/m | −41.36% (below 0%: shrinking) | 100.00% | (9,245.19%) | Compare |
| TELO Telomir Pharmaceuticals, Inc. | $57.5M | — (loss-making) | — | — | n/m | −45.34% (below 0%: shrinking) | — | 0.00% | Compare |
| CRBP Corbus Pharmaceuticals Holdings, Inc. | $55.3M | — (loss-making) | — (loss-making) | −92.09% (below 0%: shrinking) | n/m | −78.52% (below 0%: shrinking) | 0.00% | 0.00% | Compare |
| Median of peers | $60.7M | — | — | −14.05% | — | −96.94% | 25.27% | 0.00% |
Pay and ownership Proxy statement filed 29 May 2026
Ownership
Directors and executive officers, together
5.30%
Falcon Creek Capital Advisor LLC
25.91%
Ownership is the proxy’s own table: the directors and officers as a group, and every holder of 5% or more.
Read the proxy statement